Beranda › Sistem Imun dan Gangguan › Texas
Uji klinis Sistem Imun dan Gangguan di Texas
14 studi untuk Sistem Imun dan Gangguan mencari peserta di lokasi di Texas.
Kota di Texas
Teks studi resmi (Bahasa Inggris)
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- The University of Texas - MD Anderson Cancer Center, Houston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07192471A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
- Jade Clinical Site, Houston
Menerima pesertaFase 2
Usia 18 hingga 60 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07541287A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Baylor College of Medicine, Houston
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT06722235Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- The Don and Sybil Harrington Cancer Center, Amarillo
- Audie L Murphy VA Hospital, San Antonio
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT04242095(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- The University of Texas MD Anderson Cancer Center, Houston
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT04996875A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Baylor College of Medicine, Houston
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06948318Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Baylor University Medical Center, Dallas
- Texas Transplant Institute, San Antonio
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT05826535Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
- Dallas Renal Group, Dallas
- Dallas Renal Group, Dallas
- Nephro Asso North Illinois Indiana, Houston
Menerima pesertaFase 3
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT06858319Music-4-MS to Improve Cognition in People Living With Multiple Sclerosis: A Feasibility Study
- University of Texas at Austin, Austin
Menerima peserta
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT07759115A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Inmagene Site 8, Southlake
Menerima pesertaFase 2
Usia 18 hingga 74 · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT07037901A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition
- Texas Children's Hospital, Houston
Menerima pesertaFase 2
Semua usia · Semua jenis kelamin · Diperbarui 2 Jun 2026 · NCT05787574A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
- UT Southwestern Medical Center, Dept. of Dermatology, Dallas
- MD Anderson Texas Medical Center, Houston
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Mei 2026 · NCT04422912CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- The University of Texas MD Anderson Cancer Center, Houston
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Apr 2026 · NCT03328078A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- St. David's South Austin Medical Center, Austin
- UT Southwestern Medical Center, Dallas
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Des 2025 · NCT06619561Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.